BST-CarGel PIII Results soon . This stock is flying under Radar ..
Positive Final- Data will push this stock over 1$ !!
Market Cap : 10,5 Mio $
Price : 0,105 $
BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel® Cartilage Repair Device
June 17, 2009
Not yet approved by Health Canada, the FDA or the European authorities
BST-CarGel® is aimed at treating focalized cartilage lesions, either from trauma (sports injury or accident) or from secondary osteoarthritis (OA) degeneration.
Arthroscopic view of
a cartlage lesion
The various surgical techniques (microfactures, mosaicplasty, autologous chondrocyte implantation) currently used all have their drawbacks including complicated or multiple surgeries, high cost and/or poor outcomes.
Orthopedic surgeons perform 1.6 million of knee arthroscopic procedures each year in the USA. Cartilage lesions are found in a large number of these procedures.
Additionally, a number of patients too young for arthroplasty, suffering from secondary osteoarthritic focal lesions due to previous trauma, body weight, mis-alignment of the joint or from a previous meniscal surgery, may be good candidates for BST-CarGel®. Osteoarthritis affects around 10% of the population. In the USA alone, it represents 21 million people, out of whom around 65% suffer from OA of the knee.
Cartilage lesions in other joints such as the hip, ankle and the shoulder could potentially benefit from BST-CarGel®.
BST-CarGel® will be more cost-effective than the overly-expensive cell-based therapies to address the challenges of the various healthcare systems around the worl